Cuorips Inc. Logo

Cuorips Inc.

Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.

4894 | T

Overview

Corporate Details

ISIN(s):
JP3266030000
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号 日本橋ライフサイエンスビルディング2、507
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cuorips Inc. is a regenerative medicine company engaged in the research, development, manufacturing, and commercialization of cell-based therapeutic products. The company specializes in advanced technologies involving induced pluripotent stem (iPS) cells. Its flagship development is the world's first iPS cell-derived cardiomyocyte sheet, a novel treatment targeting severe heart failure. In addition to its own product pipeline, Cuorips is involved in optimizing manufacturing and quality processes and offers contract development services to contribute to the broader advancement of medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:13
Registration Form
確認書
Japanese 8.1 KB
2025-11-13 08:07
Interim Report
半期報告書-第10期(2025/04/01-2026/03/31)
Japanese 199.3 KB
2025-06-25 08:39
Post-Annual General Meeting Information
臨時報告書
Japanese 22.9 KB
2025-06-20 08:39
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 08:38
Governance Information
内部統制報告書-第9期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:37
Annual Report
有価証券報告書-第9期(2024/04/01-2025/03/31)
Japanese 2.3 MB
2024-11-14 02:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 02:24
Interim Report
半期報告書-第9期(2024/04/01-2025/03/31)
Japanese 162.2 KB
2024-07-01 02:38
Post-Annual General Meeting Information
臨時報告書
Japanese 22.2 KB
2024-06-27 09:38
Governance Information
内部統制報告書-第8期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:37
Registration Form
確認書
Japanese 8.1 KB
2024-06-27 09:36
Annual Report
有価証券報告書-第8期(2023/04/01-2024/03/31)
Japanese 2.9 MB
2024-02-13 07:36
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-02-13 07:36
Quarterly Report
四半期報告書-第8期第3四半期(2023/10/01-2023/12/31)
Japanese 132.3 KB
2023-11-10 08:29
Report Publication Announcement
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all Cuorips Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cuorips Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cuorips Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.